American Association for Cancer Research
00085472can123950-sup-figleg.pdf (46.03 kB)

Supplementary Figure Legend from Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma

Download (46.03 kB)
journal contribution
posted on 2023-03-30, 22:23 authored by Rachel G. Liao, Joonil Jung, Jeremy Tchaicha, Matthew D. Wilkerson, Andrey Sivachenko, Ellen M. Beauchamp, Qingsong Liu, Trevor J. Pugh, Chandra Sekhar Pedamallu, D. Neil Hayes, Nathanael S. Gray, Gad Getz, Kwok-Kin Wong, Robert I. Haddad, Matthew Meyerson, Peter S. Hammerman

PDF file - 46K



A comprehensive description of genomic alterations in lung squamous cell carcinoma (lung SCC) has recently been reported, enabling the identification of genomic events that contribute to the oncogenesis of this disease. In lung SCC, one of the most frequently altered receptor tyrosine kinase families is the fibroblast growth factor receptor (FGFR) family, with amplification or mutation observed in all four family members. Here, we describe the oncogenic nature of mutations observed in FGFR2 and FGFR3, each of which are observed in 3% of samples, for a mutation rate of 6% across both genes. Using cell culture and xenograft models, we show that several of these mutations drive cellular transformation. Transformation can be reversed by small-molecule FGFR inhibitors currently being developed for clinical use. We also show that mutations in the extracellular domains of FGFR2 lead to constitutive FGFR dimerization. In addition, we report a patient with an FGFR2-mutated oral SCC who responded to the multitargeted tyrosine kinase inhibitor pazopanib. These findings provide new insights into driving oncogenic events in a subset of lung squamous cancers, and recommend future clinical studies with FGFR inhibitors in patients with lung and head and neck SCC. Cancer Res; 73(16); 5195–205. ©2013 AACR.

Usage metrics

    Cancer Research



    Ref. manager